CACNA1C and acute myeloblastic leukemia with maturation: Cav1.2 is a potential therapeutic target for inhibiting invasiveness during AM progression, necessitating a deeper understanding of the regulatory mechanisms mediating Ca2+ signaling invasiveness through Cav1.2 (35).